Monitoring propranolol treatment in periocular infantile haemangioma

R Burne1, R Taylor2,

  • 1Hull York Medical School, Heslington, York, UK.

Eye (London, England)
|October 18, 2014
PubMed

Insights

A new tool, the delta defocus equivalent (DFE-∂), quantifies amblyopic risk from periocular haemangioma. Propranolol treatment significantly reduced this risk in children, aiding treatment decisions.

Area of Science:

  • Ophthalmology
  • Paediatric Ophthalmology
  • Optometry

Background:

  • Periocular infantile haemangiomas can induce anisometropia, leading to amblyopic risk.
  • Accurate assessment of this risk is crucial for effective management.
  • Current methods may not fully capture the dynamic nature of the risk during treatment.

Purpose of the Study:

  • To develop a quantitative tool for assessing amblyopic risk.
  • To monitor the treatment effect of propranolol on this risk.
  • To aid clinical decision-making in managing periocular haemangiomas.

Main Methods:

  • A study involving nine children treated with propranolol for periocular haemangioma.
  • Development of the delta defocus equivalent (DFE-∂) as a measure of induced anisometropia.
  • Retrospective collection of refraction data to track DFE-∂ trends during treatment.

Main Results:

  • The average DFE-∂ at the start of propranolol treatment was 1.54 dioptres.
  • The average DFE-∂ decreased to 0.39 dioptres by the end of treatment.
  • A significant reduction in amblyogenic risk was observed.

Conclusions:

  • The DFE-∂ serves as a valuable tool for assessing amblyopic risk in infantile haemangioma.
  • This quantitative measure can support treatment decisions in paediatric ophthalmology.
  • Propranolol treatment effectively mitigates amblyopic risk associated with periocular haemangiomas.
Abstract